* Rigel Pharmaceuticals Inc reported quarterly breakeven results per share for the quarter ended in December, lower than the same quarter last year, when the company reported EPS of 1 cents. The mean expectation of six analysts for the quarter was for a loss of 3 cents per share. Wall Street expected results to range from -5 cents to -1 cents per share.
* Revenue fell 30.2% to $35.79 million from a year ago; analysts expected $34.10 million.
* Rigel Pharmaceuticals Inc's reported EPS for the quarter was breakeven results.
* The company reported quarterly net income of $737 thousand.
* Rigel Pharmaceuticals Inc shares had risen by 1.4% this quarter.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 28.6% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $2.00
This summary was machine generated from LSEG data March 5 at 11:33 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -0.03 0.00 Beat
Sep. 30 2023 -0.07 -0.03 Beat
Jun. 30 2023 -0.08 -0.04 Beat
Mar. 31 2023 -0.10 -0.08 Beat
Comments